By Kyle Morris

Shares in ImmuPharma rose 11% on Thursday after the company said it received positive guidance from the U.S. Food and Drug Administration that supports an Investigational New Drug application and a phase 2/3 adaptive clinical trial of the P140 platform for patients with chronic idiopathic demyelinating polyneuropathy.

Shares at 0850 GMT were up 0.33 pence at 3.40 pence.

The company said the FDA feedback recognised that P140 is suitable to be studied in another disease indication in addition to systemic lupus erythematosus, which supports P140 across several auto-immune/inflammatory diseases.

An IND application will now be prepared for submission to the FDA.

An application for Orphan Drug status for CIDP will be also submitted in parallel to the full IND application.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

May 18, 2023 05:23 ET (09:23 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Immupharma.
Immupharma (LSE:IMM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Immupharma.